A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Clinical trial NCT06987539 · RECRUITING
Trial details
- NCT number
- NCT06987539
- Sponsor
- Amgen
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-31
- Primary completion
- 2030-03-13
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.